

# Solution marks milestone amid GLP-1 surge

**Evernorth EncircleRx<sup>SM</sup>: Cardiodiabesity continues to evolve to meet ever-changing market demands**



The U.S. Food and Drug Administration (FDA) approved Wegovy<sup>®</sup> for weight loss in 2021 and Zepbound<sup>®</sup> in 2023. GLP-1 indications are now poised for further expansion with new indications for osteoarthritis of the knee, Major Adverse Cardiovascular Events (MACE) and the recent approval of Wegovy for Metabolic Dysfunction-Associated Steatohepatitis (MASH). Manufacturers are also planning to launch new easier-to-take oral formulations that could further fuel demand.<sup>1</sup>


**With over 40% of U.S. adults struggling with obesity,<sup>2</sup>** demand for GLP-1s is already high. As more members turn to these medications, the need for controlling costs will continue to grow. Last year, nearly half of the total increase in drug spend was attributable to drugs used for weight management.<sup>3</sup>



Doctors have prescribed GLP-1s to treat diabetes for more than **20 years**

## Evernorth EncircleRx<sup>SM</sup>: Cardiodiabesity addresses the needs of plan sponsors covering GLP-1s

The solution helps members reach their goals by encouraging healthy habits and helps plan sponsors manage costs by ensuring those who need the medications most have access.



**Earlier this year we published EncircleRx's success after the first six months**

Now, one year later we have even more to be excited about.

**EncircleRx has enrolled 11 million+ people since launching last year**

This rapid growth reflects the need for strategies that help support plan sponsors as GLP-1 use becomes more widespread and more clinical indications are approved.



## How it works

EncircleRx gives plan sponsors looking to cover GLP-1s more optionality in managing cardiometabolic conditions by providing trend management and spend predictability. The program manages utilization by using medical data to ensure that those who need the medications are able to get them.

EncircleRx also promotes the member's long-term wellness by linking them with lifestyle modification programs where they can get personalized guidance for the best outcomes in their weight loss journey. To keep off-label and inappropriate prescribing at bay, EncircleRx proactively prevents fraud, waste and abuse with GLP-1 anti-fraud protection.

## Supporting lifestyle changes throughout the wellness journey

EncircleRx provides plans with optionality in managing weight loss trend. Plans can choose to mitigate trend while maintaining access with a  $\text{BMI} \geq 32$  threshold or to further restrict their eligible population with a  $\text{BMI} \geq 35$  threshold and cover weight loss GLP-1s for their most vulnerable members. Members with a BMI of 35 or higher are classified as severely obese and are most in need of a benefit that provides medications and sustainable lifestyle change.

Lifestyle change is an essential component to EncircleRx. Since launching, the program has expanded to give plan sponsors more choice in lifestyle modification programs. Omada for Prevention and Weight Health, Teladoc Health and 9amHealth are now available for plan sponsors to select what works best for their member population.

Members enrolled in Omada said the program earned their trust, even if they had uncertainty at first. As they engaged with the program's features—such as updates, reminders, and educational content—they came to see its value.

Members called out the personalized coaching Omada offers. Coaches keep up routine contact, ask thoughtful questions, and tailor comments to each person's progress. Group discussions add another layer of community as members share experiences.

Year-one member feedback shows the impact of lifestyle modification programs. About 80% of members exceeded their program benchmarks in year one. Collectively, members lost more than two million pounds.

## EncircleRx by the numbers<sup>4</sup>

**7.7%** average decrease in members' BMI

**\$400M+** in client savings\*

**2M+** pounds were collectively lost by members

**Up to 40%** reduction in client's trend when enrolled in program

**~80%** of members exceeded their program benchmarks in year one

## Safeguarding access

EncircleRx promotes appropriate prescribing and pharmacy management. **This multi-layered approach includes:**



### Appropriate prescriber and pharmacy management

Encourages appropriate prescribing, dispensing, and adherence.



### Monitoring for misuse

Detects fraud, waste, and abuse such as stockpiling, doctor-shopping, or forging lab results.



### Preventing diversion

Flags behaviors linked to illegal prescription drug use.



### Engaging prescribers

Partnered with 250+ providers to raise awareness and improve prescribing practices.



### Delivering results

Cut high-risk prescribing by 25% in year one.

## The future of GLP-1s and promising new indications

GLP-1s have shown potential beyond diabetes treatment and weight loss. Research points to applications for a wide range of conditions, including substance use disorders and neurodegenerative diseases such as Alzheimer's.<sup>5</sup>

As the demand for GLP-1s continue to skyrocket and the indications for the drugs continue to expand, EncircleRx is helping plan sponsors meet the emerging need by managing trend and driving down costs to keep GLP-1s affordable.

### Here's how:

#### Highly automated prior authorization (PA) option:

To address a growing trend of direct-to-consumer GLP-1 purchases, EncircleRx offers a highly automated utilization program option. This option focuses on the lowest plan net cost per prescription and keeps member copays at no more than \$200—lower than current direct-to-consumer offerings on the market.

#### Expanded vendor network:

EncircleRx lifestyle modification program options have expanded, providing plan sponsors with the choice of Teladoc Health and 9amHealth, in addition to Omada.

#### Greater utilization controls:

Plan sponsors can now select how much control they want to add to their utilization strategy based on a member's BMI.




# Looking ahead

GLP-1s are reshaping the health care landscape. Evernorth continues to be committed to driving innovation in the GLP-1 space by continuously exploring new therapeutics and indications to meet the evolving needs of the market.

RX

**EncircleRx delivers highly automated PA options, more lifestyle modification program choice, and enhanced utilization management strategies** that ensure affordability, appropriate prescribing, and access to GLP-1s for those who need them most.



\*Program cost avoidance savings

1. PwC. "From Molecules to Milestones: Reinventing for the Future of Weight Loss Drugs." <https://www.pwc.com/us/en/services/consulting/business-model-reinvention/glp-1-trends-and-impact-on-business-models.html>. Page reviewed: October 2, 2025.
2. Centers for Disease Control and Prevention (CDC). "Adult Obesity Facts." [www.cdc.gov/obesity/adult-obesity-facts](http://www.cdc.gov/obesity/adult-obesity-facts). Page last reviewed: May 14, 2024.
3. Evernorth Health Services. (2025). "Pharmacy in Focus: Navigating the GLP-1 Conundrum."
4. Evernorth Book of Business data, 2025.
5. The Lancet Discovery Science. "The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions." <https://pmc.ncbi.nlm.nih.gov/articles/PMC12303005>. Page last reviewed: July 17, 2025.

All Evernorth Health Services products and services are provided exclusively by or through affiliates of the Evernorth companies, including Evernorth Care Solutions, Inc., Evernorth Behavioral Health, Inc., Evernorth Behavioral Health of Texas, Inc. and Evernorth Behavioral Health of California, Inc.

© 2025 Evernorth Health Services. All rights reserved. Some content provided under license.

**EVERNORTH**  
HEALTH SERVICES